Gibson Dunn Represented XOMA Royalty in Its Acquisition of LAVA Therapeutics
Firm News | August 13, 2025
Gibson Dunn represented XOMA Royalty Corporation in its acquisition of clinical-stage immuno-oncology company LAVA Therapeutics N.V.
Our team included partners Ryan Murr and Branden Berns and associates Evan Shepherd and Advait Ramanan. Partner Pamela Lawrence Endreny and associate Betsy Johnson advised on tax. Partner Sean Feller advised on executive benefits.